77.3% of Population Received First Vaccine Dose... Total 39,714,000 People (Comprehensive)

[Image source=Yonhap News]

[Asia Economy Reporter Lee Jung-yoon] As the COVID-19 vaccination completion rate exceeded 50% of the total population, about 3,400 people received their first dose and about 33,000 people completed their vaccination on the 3rd.

According to the COVID-19 Vaccination Response Promotion Team (Promotion Team) on the 4th, the number of new first-dose vaccinations the previous day was 3,404, and the number of completed vaccinations was 33,187.

The total number of new first and second doses administered in one day was 36,591. The number of vaccinations recorded about 1.09 million on Friday, the 1st, dropped to about 530,000 on the 2nd, and then sharply decreased to about 36,000 the previous day. This was due to some entrusted medical institutions and vaccination centers being closed or operating on reduced hours during the weekend and holidays.

By vaccine type, the number of new first-dose vaccinations was 2,548 for Moderna, 765 for Pfizer, 80 for Janssen, and 11 for AstraZeneca (AZ).

As of midnight that day, the cumulative number of first-dose vaccinations in Korea was 39,714,000, which corresponds to 77.3% of the total population (51,349,116 as of December last year). The first-dose vaccination rate among the population aged 18 and over is 89.9%. Looking at the cumulative first-dose vaccinations by vaccine, Pfizer accounts for 21,195,087, AstraZeneca 11,092,334, and Moderna 5,979,026. The cumulative number of Janssen vaccine recipients is 1,447,553. People who received the Janssen vaccine, which requires only one dose, are counted in both the first and second dose figures.

The vaccination rate by gender shows that both the first-dose vaccination rate and the completion rate are slightly higher for women than for men.

Among women, 20,064,159 out of 25,746,790 eligible individuals (77.9%) completed the first dose, which is higher than men, with 19,649,841 out of 25,602,326 (76.8%) having received the first dose.

As of midnight that day, the vaccination completion rate was 54.3% for women and 50.9% for men, with more than half of the eligible population in both genders having completed vaccination.

By age group, the vaccination completion rate was highest among those in their 70s at 90.1%, followed by those in their 60s at 88.5%, those aged 80 and above at 80.1%, and those in their 50s at 79.5%. Among the younger and middle-aged groups, where vaccination started relatively late, the rates were 40.4% for those in their 30s, 38.2% for those in their 40s, 37.7% for those aged 18?29, and 0.2% for those under 17, all still below half.

As of midnight that day, the total remaining vaccine doses in Korea amounted to 18,953,200.

By vaccine type, there were 7,688,100 doses of Moderna, 6,623,500 doses of Pfizer, 4,416,600 doses of AstraZeneca, and 225,000 doses of Janssen remaining.

The number of people vaccinated with 'leftover vaccines' through standby lists managed by medical institutions or social networking service (SNS) applications such as Naver and Kakao increased by 2,126 for the first dose (516 from standby lists and 1,610 from same-day SNS reservations) and by 5,748 for the second dose (927 from standby lists and 4,821 from same-day SNS reservations).

Thus, the cumulative number of people vaccinated with leftover vaccines reached 5,001,590 for the first dose and 1,064,359 for completed vaccinations.

Among the 33,187 people who newly completed their second dose the previous day, 24,878 received Pfizer, 8,121 received Moderna, and 108 received AstraZeneca. Although 412 people were counted as having completed AstraZeneca vaccination, 304 of them received AstraZeneca for the first dose and Pfizer for the second dose as a mixed vaccination.

As a result, the total number of people who completed the second dose reached 27,016,188. This corresponds to 52.6% of the population and 61.2% of the population aged 18 and over.

The cumulative number of completed vaccinations by vaccine type is 12,822,004 for Pfizer, 10,437,266 for AstraZeneca (including 1,637,088 mixed vaccinations), 2,309,365 for Moderna, and the remainder are Janssen recipients.

This content was produced with the assistance of AI translation services.